<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632645</url>
  </required_header>
  <id_info>
    <org_study_id>P060211</org_study_id>
    <nct_id>NCT00632645</nct_id>
  </id_info>
  <brief_title>Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride</brief_title>
  <acronym>NEUROHD</acronym>
  <official_title>Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in
      average (with high variability) in the fourth decade. The disease progression is classically
      characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders
      (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining
      depression and irritability) and metabolic disorder (cachexia). The disease is fatal within
      15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the
      only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also
      beneficial and adverse effects on other disease characteristics (motor, psychiatric,
      cognitive or metabolic). Their profile between beneficial and adverse effects could be
      different according the neuroleptics and their classification. The aim of this study is to
      compare beneficial and adverse effects of 3 different neuroleptics in HD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We proposed a randomized controlled trial, including 180 patients, in 3 groups: Olanzapine,
      Tetrabenazine and Tiapride, followed during 12 months. These treatments have been selected
      according their profile and their frequency of use.

      The principal criteria is the Independence scale, one of the functional scales of the Unified
      Huntington's Disease Rating Scale, the only validated scale in HD.

      Secondary criteria will assess motor,functional, psychiatric and cognitive functions,
      metabolic parameters, tolerance and cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">April 28, 2017</completion_date>
  <primary_completion_date type="Actual">April 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Independence scale</measure>
    <time_frame>at 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>motor scale</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric scale</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function scale</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function scale (TFC and Functionnal Appreciation Scale)</measure>
    <time_frame>at 3, 6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine Mylan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xenazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiapridal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olanzapine Mylan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenazine</intervention_name>
    <description>Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>tetrabenazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiapridal</intervention_name>
    <description>Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day</description>
    <arm_group_label>3</arm_group_label>
    <other_name>tiapride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic disease with motor, behavioural and/or psychiatric disorder required
             medical treatment.

          2. HD diagnosed with abnormal number of CAG repeats: 38 ≤ nucleotide expansion (CAG)
             (amendment n°5 suppressed the limit ≤ 48)

          3. Neuroleptic Prescription required.

          4. Age ≥ 18 (amendment n°5 suppressed the limit ≤ 65 years old)

          5. Patient gave its written consent

          6. Realization of medical examination and a Electroencephalogram

        Exclusion Criteria:

          1. Severe cognitive impairment or neuropsychiatric troubles.

          2. Existing diabetes.

          3. Neuroleptic prescription forbidden according to the neurologist decision.

          4. Current participation to another clinical trial.

          5. No drug compliance to previous treatment.

          6. No national health insurance affiliation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Catherine BACHOUD LEVI, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington</keyword>
  <keyword>Neuroleptic</keyword>
  <keyword>Unified Huntington Disease Rating Scale (UHDRS)</keyword>
  <keyword>Independence Scale</keyword>
  <keyword>Neuroleptic Prescription required</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Tiapride Hydrochloride</mesh_term>
    <mesh_term>Tetrabenazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

